Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTC:COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr. Hysek AG toward an exclusive partnership for the import and distribution of licensed MDMA and psilocybin products into Australia, of which detailed commercial aspects are expected by this August 31.
澳大利亞大麻和迷幻藥公司克雷索製藥有限公司(場外交易代碼：COPHF)簽署意向書(LOI)與瑞士藥房合作Apotheke Dr.Hysek AG達成獨家合作夥伴關係，將獲得許可的MDMA和裸蓋菇素產品進口和分銷到澳大利亞，詳細的商業方面預計將於今年8月31日之前公佈。
The Biel-based pharmacy is a Good Manufacturing Practice (GMP)-compliant facility manufacturing MDMA, synthetic psilocybin and LSD under Pharma GMP conditions and is authorized by the Swiss medicine agency (Swissmedic) and the country's Federal Office of Public Health (FOPH.)
這家位於貝爾的藥房是一家符合良好製造規範(GMP)的工廠，在Pharma GMP條件下生產MDMA、合成裸蓋菇素和LSD，並獲得瑞士醫藥機構(Swissmedic)和瑞士聯邦公共衛生辦公室(FOPH)的授權。
Founder Dr. Cedric Hysek works closely with Dr. Matthias Liechti, a University Hospital Basel (UHB) professor involved with the Swiss limited-use psychedelics program and leading several MindMed (NASDAQ:MNMD)-backed studies.
創始人塞德里克·希塞克博士與以下公司密切合作馬蒂亞斯·利奇提博士他是巴塞爾大學醫院的教授，參與了瑞士限用迷幻藥專案，並領導了幾項由納斯達克(Sequoia Capital：MNMD)支持的研究。
Following Australia's new legal framework for psychedelic-assisted therapies effective in July, Creso Pharma will provide import infrastructure, warehouse and product distribution through its wholly-owned subsidiary Health House International (HHI.)
根據澳大利亞7月份生效的迷幻輔助療法的新法律框架，Creso Pharma將通過其全資子公司Health House International(HHI)提供進口基礎設施、倉庫和產品分銷。
HHI holds wholesale and manufacturer licenses aligned with TGA guidelines and will apply for an import permit through the country's Office of Drug Control for this specific import and involving clinical purposes only.
HHI持有與TGA指南一致的批發和製造商許可證，並將通過該國藥物管制辦公室為這一特定進口申請進口許可證，僅涉及臨床用途。
The Creso-HHI team says they are discussing with several Australian stakeholders including GPs, pharmacists and practicing psychiatrists to form alliances with health professionals willing to enter the sector.
Creso-HHI團隊表示，他們正在與包括全科醫生、藥劑師和執業精神病學家在內的幾個澳大利亞利益相關者討論，與願意進入該行業的衛生專業人員結成聯盟。
Creso Pharma CEO and managing director William Lay says the new LOI "sets out the terms and parameters" for the licensed import and distribution to Australia of approved MDMA and psilocybin products "manufactured by one of the world's foremost practitioners in this space."
克雷索製藥董事首席執行官兼管理人員威廉·雷新的意向書說，新的意向書為獲得許可的進口和向澳大利亞分銷經批准的MDMA和裸蓋菇素產品設定了條款和參數，這些產品是由該領域世界上最重要的從業者之一製造的。
Lay said Dr. Hysek is "undoubtedly a pioneer" in applying MDMA and psilocybin treatments for better patient outcomes, collaborating with Swiss regulators and university researchers. Hysek said he hopes the new deal will result in benefitting from the Swiss knowledge and experience toward making the Australian healthcare industry work for the patients' benefit.
雷說，希塞克博士與瑞士監管機構和大學研究人員合作，在應用MDMA和裸蓋菇素治療以獲得更好的患者結果方面，無疑是一個先驅。希塞克說，他希望新協定能從瑞士的知識和經驗中受益，讓澳大利亞的醫療保健行業為患者造福。
See also: Building Australia's Psychedelics Industry: A New Joint Venture And Why It's Important
另見：建立澳大利亞的迷幻藥產業：一家新的合資企業及其重要性
That intention is echoed by Dr. Liechti, who says the knowledge from the 2015-and-running Swiss collaborative approach between federal regulators, researchers and medical professionals for "improved patient outcomes" has the potential to be shared "with both the TGA and key stakeholders in the Australian healthcare industry" toward developing "similarly effective programs" in the country's market.
這一意圖得到了利奇提博士的回應，他表示，聯盟監管機構、研究人員和醫療專業人員之間2015年來一直在合作的方法所獲得的知識，有可能與TGA和澳大利亞醫療行業的關鍵利益相關者分享，在該國市場上開發“類似有效的專案”。
"As a research partner of the Swiss limited-use program since inception, I have a direct interest in assisting in the efficient and regulated rollout of these medical applications to other jurisdictions and would embrace the opportunity to work closely with the Australian medical industry towards that goal," Liechti concluded.
作為瑞士有限用途計劃的研究夥伴，我從一開始就對協助將這些醫療應用有效和規範地推廣到其他司法管轄區有直接的興趣，並將抓住與澳大利亞醫療行業為實現這一目標密切合作的機會，利奇蒂總結道。
Photo: Benzinga edit with photo by RF_studio on Pexels and anaterate on Pixabay.
圖片來源：Pexels上的Benzinga編輯照片和Pixabay上的Anaterate。
譯文內容由第三人軟體翻譯。